Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease

• Published in: Journal of pharmacy & pharmaceutical sciences Vol. 27; p. 13199
• Main Authors: Shang, Rui, Rodrigues, Brian
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 16.07.2024
• Subjects: Animals; atherosclerosis; cardiomyocytes; cardiomyopathy; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - metabolism; Diabetes Mellitus - drug therapy; Diabetes Mellitus - metabolism; fatty acid metabolism; Fatty Acids - metabolism; Humans; lipoprotein; Lipoprotein Lipase - metabolism; Obesity - drug therapy; Obesity - metabolism; Science Archive; atherosclerosis; cardiomyocytes; cardiomyopathy; lipoprotein; fatty acid metabolism
• ISSN: 1482-1826; 1482-1826
• DOI: 10.3389/jpps.2024.13199

Worldwide, the prevalence of obesity and diabetes have increased, with heart disease being their leading cause of death. Traditionally, the management of obesity and diabetes has focused mainly on weight reduction and controlling high blood glucose. Unfortunately, despite these efforts, poor medication management predisposes these patients to heart failure. One instigator for the development of heart failure is how cardiac tissue utilizes different sources of fuel for energy. In this regard, the heart switches from using various substrates, to predominantly using fatty acids (FA). This transformation to using FA as an exclusive source of energy is helpful in the initial stages of the disease. However, over the progression of diabetes this has grave end results. This is because toxic by-products are produced by overuse of FA, which weaken heart function (heart disease). Lipoprotein lipase (LPL) is responsible for regulating FA delivery to the heart, and its function during diabetes has not been completely revealed. In this review, the mechanisms by which LPL regulates fuel utilization by the heart in control conditions and following diabetes will be discussed in an attempt to identify new targets for therapeutic intervention. Currently, as treatment options to directly target diabetic heart disease are scarce, research on LPL may assist in drug development that exclusively targets fuel utilization by the heart and lipid accumulation in macrophages to help delay, prevent, or treat cardiac failure, and provide long-term management of this condition during diabetes.